Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
复制标题
血清可溶性CD26/DPP4滴度变化是人源化抗CD26抗体治疗癌症的潜在预后生物标志物。
DOI：
10.1186/s40364-021-00273-0
复制
发表时间：
2021-03-23
影响因子：
11.1
通讯作者：
Morimoto C
中科院分区：
文献类型：
--
作者：
Kaneko Y;Hatano R;Hirota N;Isambert N;Trillet-Lenoir V;You B;Alexandre J;Zalcman G;Valleix F;Podoll T;Umezawa Y;Takao S;Iwata S;Hosono O;Taguchi T;Yamada T;Dang NH;Ohnuma K;Angevin E;Morimoto C
人源化抗CD 26单克隆抗体YS 110用于表达CD 26的肿瘤的I期试验最近进行。本研究基于I期数据确定了CD 26靶向治疗的潜在预后生物标志物。采用箱须图分析、散点图分析、Peason积差相关/斯皮尔曼秩差相关、条形图分析和受试者工作特征（ROC）分析sCD 26滴度随YS 110给药的变化与肿瘤体积变化、RECIST标准评价和无进展生存期（PFS）的相关性。通过体外实验证实了血清sCD 26滴度变化的机制。血清sCD 26/DPP 4滴度在YS 110给药后降低，并逐渐恢复，直至下次输注。与疾病进展病例相比，疾病稳定（SD）病例在下次输注前的血清sCD 26/DPP 4滴度维持在较低水平。ROC分析将SD临床结局的第29天前/后血清sCD 26/DPP 4滴度变化的截止值定义为肿瘤缓解或PFS。体外实验证实，添加YS 110减少了表达CD 26的肿瘤和非肿瘤细胞的sCD 26产生。我们的研究表明，血清sCD 26/DPP 4滴度在YS 110治疗早期的变化是评估治疗效果的预测性生物标志物。在线版本包含补充材料，可通过10.1186/s40364-021-00273-0获得。
The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Box and Whisker plot analysis, Scatter plot analysis, Peason product moment correlation/Spearman’s rank-difference correlation, Bar graph analysis, and Receiver Operating Characteristics (ROC) were used to examine the correlation between sCD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). Mechanism for serum sCD26 titer variation was confirmed by in vitro experimentation. Serum sCD26/DPP4 titer was reduced following YS110 administration and gradually recovered until the next infusion. Serum sCD26/DPP4 titer before the next infusion was sustained at lower levels in Stable Disease (SD) cases compared to Progressive Disease cases. ROC analysis defined the cut-off level of serum sCD26/DPP4 titer variation at day 29 pre/post for the clinical outcome of SD as tumor response or PFS. In vitro experimentation confirmed that YS110 addition reduced sCD26 production from CD26-expressing tumor and non-tumor cells. Our study indicates that serum sCD26/DPP4 titer variation in the early phase of YS110 treatment is a predictive biomarker for evaluating therapeutic efficacy. The online version contains supplementary material available at 10.1186/s40364-021-00273-0.
登录
查看更多内容
影响因子：
--
作者：
De Chiara, Loretta;Paez de la Cadena, Maria;Cordero, Oscar J.
通讯作者：
Cordero, Oscar J.
影响因子：
2.6
作者：
Hatano R;Yamada T;Matsuoka S;Iwata S;Yamazaki H;Komiya E;Okamoto T;Dang NH;Ohnuma K;Morimoto C
通讯作者：
Morimoto C
影响因子：
11.5
作者：
Inamoto, Teruo;Yamochi, Tadanori;Morimoto, Chikao
通讯作者：
Morimoto, Chikao
影响因子：
2.7
作者：
Iwaki-Egawa, S;Watanabe, Y;Fujimoto, Y
通讯作者：
Fujimoto, Y
影响因子：
--
作者：
Liang PI;Yeh BW;Li WM;Chan TC;Chang IW;Huang CN;Li CC;Ke HL;Yeh HC;Wu WJ;Li CF
通讯作者：
Li CF